Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

The scheduled October 20 earnings date appears unconfirmed: the latest verified company earnings filing found was July 22, and the SEC company listing showed no later earnings 8-K at review. [SEC company filings](https://www.sec.gov/edgar/browse/?CIK=709337) No earnings-linked market reaction or analyst revision can therefore be established. The deterministic prior has shifted negative from the earlier positive baseline, warranting monitoring rather than a post-print bullish call. Sentiment metrics other than headline buzz are unavailable; zero placeholders should not be interpreted as measured neutral readings.

The supplied price anchor is a pre-results October 20 close, not a post-earnings reaction. No Q4 beat or miss, October 28 guidance revision, subsequent analyst change, or reaction can be verified yet. The October 19 debt filing is relevant but not an earnings release. Sentiment fields without coverage are placeholders, not measured signals; the sparse recent-news packet and absent social coverage lower conviction.

The company release and SEC exhibit provide strong primary evidence, and the beat warrants a positive revision to the prior neutral monitoring thesis. The $357.75 anchor is the October 20 close, before the after-hours release. An indicative October 21 premarket quote of $356.45 at 08:05 ET was about 0.36% lower, but it is not a confirmed regular-session reaction: https://www.investing.com/equities/chubb-corp-historical-data . Initial analyst evidence is limited to a Neutral reiteration; missing broader revisions are not positive evidence. No sufficient social, options, short-interest or employee data were supplied, so zero placeholders in the sentiment object are unavailable values rather than measured readings.

News tone is mixed: strong unit revenue contrasts with a fuel-driven full-year loss outlook. Against the packet's $34.36 October 20 close, a market-data page showed $34.40 at 8:40 a.m. ET on October 21, roughly +0.1% in premarket trading; that thin early indication does not establish a sustained post-earnings reaction. https://stockanalysis.com/stocks/alk/ No verified post-print analyst revisions were available at the cutoff. Social, options, short-interest and employee-rating figures are unavailable; their zero fields are placeholders, not measured neutral readings.

Company-reported Q3 results and Axios's consensus comparison support a positive initial earnings surprise. Axios reported roughly 2% after-hours upside; Benzinga displayed about 9% premarket upside on October 21, but no regular-session post-print close was available at this cutoff. Two post-print target raises are listed by Benzinga; forward estimate revisions and quantitative company guidance were not established. Social, options, short-interest and employee metrics are unavailable, so the zero placeholders in the sentiment object should not be interpreted as measured neutral readings. [Earnings exhibit](https://www.sec.gov/Archives/edgar/data/1181412/000162828026066482/spaceexplorationtechnologi.htm) [Consensus and after-hours reaction](https://www.axios.com/2026/10/20/spacex-earnings-ai-elon-musk) [Premarket and analyst actions](https://www.benzinga.com/quote/spcx/price-targets)

The earnings tone is mixed: reported FFO and revenue modestly topped the cited consensus, but investment guidance was reduced. An early quoted October 21 premarket price of $66.78 was about 0.45% below the $67.08 October 20 close; regular-session post-release reaction was not yet available, and the October 20 gain preceded the release. [Premarket quote](https://stockanalysis.com/stocks/adc/) Baird's reported $77-to-$76 target cut is an initial revision, not evidence of a broad analyst reset. Options, short-interest and social measures were unavailable; their zero placeholders above are not observations.

Dizzying positions : Judge hears arguments in lawsuit over $2B state contract awarded to politically connected firm